New Zealand Clinical Research

New Zealand Clinical Research (NZCR), formed by the merger of Auckland Clinical Studies and Christchurch Clinical Studies Trust in mid–2020, is New Zealand’s largest and leading early-phase clinical research organization. With over three decades of experience and more than 800 completed trials involving over 17,000 participants, NZCR has pioneered world-firsts such as umbrella protocols, global biosimilar studies, hepatitis C treatments that contributed to curing millions worldwide, and the first in-human CRISPR/Cas9 gene-editing trial for amyloidosis. The company operates state-of-the-art facilities across Auckland, Hamilton, Wellington and Christchurch.